PRA Health Sciences Collaborates With AMR to Accelerate Vaccine Development
September 29 2015 - 10:00AM
In an effort to accelerate new vaccines to market, PRA Health
Sciences (PRA) (NASDAQ:PRAH) is pleased to announce its
collaboration with Alliance for Multispecialty Research (AMR). This
partnership paves the way for a smarter approach to vaccine studies
that will allow studies to run more efficiently and effectively.
"This is an ideal collaboration," said Frank Hijek, PRA Senior
Vice President, Strategic Drug Development. "It combines the
expertise of PRA, one of the world's leading contract research
organizations, and AMR one of the most effective clinical research
site networks in the industry. Together, we can help sponsors get
vaccines to the people who need them."
PRA's vaccine experience includes Phase I-Phase IV adult and
pediatric studies involving nearly 213,000 study participants at
more than 3,000 sites around the world. PRA has provided clinical
development support for ten approved vaccines over the past five
years. Additionally, PRA supports four of the five top vaccine
manufacturers.
"Our partnership with PRA allows us to provide a simple approach
to effective vaccine studies," said AMR CEO Brenda Atchison. "Our
respective expertise will allow us to make significant strides in
implementing efficient solutions to smarter vaccine
development."
AMR provides clinical study services across a broad range of
therapeutic areas and has a breadth of vaccine trial experience for
a variety of vaccine indications, including several
bioterrorism-related government sponsored programs. Combining AMR
and PRA expertise will allow for successful support of small to
mid-size vaccine trials and AMR's outstanding 98% subject retention
rate will help sponsors meet or exceed enrollment timelines.
The vaccine market has traditionally been pediatric, but the
adult vaccine market continues to grow and is expected to nearly
double by 2020. Many of the vaccines under development in the adult
market segment focus on infectious diseases such as avian flu,
malaria and hepatitis, as well as cancer treatment and
prevention.
The collaboration between PRA and AMR will facilitate
identification of appropriate patient populations for vaccine
studies. This will reduce development times and help bring much
needed vaccines to market sooner.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our
clients is what we do. Side-by-side with our clients, we strive to
move drug discovery forward, helping them to develop life-saving
and life-improving drugs. PRA has more than 11,000 employees
working in 80+ countries providing comprehensive clinical
development services across all phases. From full service clinical
development to the pioneering Embedded Solutions™ model, PRA
provides a broad spectrum of solutions that meet the demands of a
diverse marketplace. PRA has worked on 100+ marketed drugs across
several therapeutic areas and conducted the pivotal or supportive
trials that led to FDA and/or international regulatory approval of
50+ such drugs.
ABOUT AMR
The Alliance for Multispecialty Research (AMR) is a unique
network of independently owned, geographically diverse, and highly
experienced Clinical Research Centers of Excellence. Chartered as a
formal organization in 1994, AMR Centers of Excellence provide
clinical trial services across a broad base of therapeutic areas to
the pharmaceutical, biotechnology, nutrition and medical device
industries. AMR is the proud recipient of the 2015 World Vaccine
Congress' Vaccines in Excellence (ViE) Award for "Best Clinical
Trial Network".
CONTACT: INQUIRIES:
Christine Rogers, Manager - Public Relations,
Corporate Communications
EMAIL: rogerschristine@prahs.com
PHONE: +1 919.786.8463
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jun 2024 to Jul 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jul 2023 to Jul 2024